HN2002000227A - Inhibidores de benzotiadiazina de metaloproteinasas de la matriz - Google Patents
Inhibidores de benzotiadiazina de metaloproteinasas de la matrizInfo
- Publication number
- HN2002000227A HN2002000227A HN2002000227A HN2002000227A HN2002000227A HN 2002000227 A HN2002000227 A HN 2002000227A HN 2002000227 A HN2002000227 A HN 2002000227A HN 2002000227 A HN2002000227 A HN 2002000227A HN 2002000227 A HN2002000227 A HN 2002000227A
- Authority
- HN
- Honduras
- Prior art keywords
- inhibitors
- benzotiadiazine
- metaloproteinase
- matrix
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 102100027995 Collagenase 3 Human genes 0.000 abstract 2
- 108050005238 Collagenase 3 Proteins 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000007658 benzothiadiazines Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Alloys Or Alloy Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26878201P | 2001-02-14 | 2001-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2002000227A true HN2002000227A (es) | 2002-10-23 |
Family
ID=23024450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2002000227A HN2002000227A (es) | 2001-02-14 | 2002-02-11 | Inhibidores de benzotiadiazina de metaloproteinasas de la matriz |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6656932B2 (https=) |
| EP (1) | EP1368327B1 (https=) |
| JP (1) | JP2004518726A (https=) |
| AT (1) | ATE280164T1 (https=) |
| BR (1) | BR0207865A (https=) |
| CA (1) | CA2433075A1 (https=) |
| DE (1) | DE60201665T2 (https=) |
| DO (1) | DOP2002000336A (https=) |
| ES (1) | ES2231708T3 (https=) |
| GT (1) | GT200200016A (https=) |
| HN (1) | HN2002000227A (https=) |
| MX (1) | MXPA03005870A (https=) |
| PA (1) | PA8538501A1 (https=) |
| PE (1) | PE20020953A1 (https=) |
| TN (1) | TNSN02013A1 (https=) |
| UY (1) | UY27155A1 (https=) |
| WO (1) | WO2002064578A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| EP1434585A1 (en) | 2001-10-12 | 2004-07-07 | Warner-Lambert Company LLC | Alkyne matrix metalloproteinase inhibitors |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
| WO2004006913A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| AU2003281169A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| BR0312708A (pt) * | 2002-07-17 | 2005-04-26 | Warner Lambert Co | Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib |
| WO2004014869A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| AU2003249477A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| MXPA05001603A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados monociclicos como inhibidores de metaloproteinasa de matriz. |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| BR0313724A (pt) | 2002-08-13 | 2005-06-28 | Warner Lambert Co | Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz |
| ES2283851T3 (es) | 2002-08-13 | 2007-11-01 | Warner-Lambert Company Llc | Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
| AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2004014377A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
| WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2004014388A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
| CA2497658A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| BR0313727A (pt) * | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de isoquinolina como inibidores de metaloproteinase da matriz |
| WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
| US7570259B2 (en) | 2004-06-01 | 2009-08-04 | Intel Corporation | System to manage display power consumption |
| EP1828152B1 (en) | 2004-12-08 | 2008-08-20 | Bristol-Myers Squibb Company | Heterocyclic compounds as inhibitors of factor viia |
| ES2395952T3 (es) | 2005-03-16 | 2013-02-18 | Toyama Chemical Co., Ltd. | Nuevo derivado del ácido antranílico o una sal del mismo |
| US8431576B2 (en) | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
| JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
| ES2765036T3 (es) | 2012-03-19 | 2020-06-05 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden esteres de ácidos grasos |
| ES2950418T3 (es) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden alcohol bencílico |
| EP2897592B1 (en) | 2012-09-19 | 2020-02-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
| CN113773277B (zh) * | 2021-09-18 | 2023-12-05 | 兰州大学 | 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法 |
| JP2025534288A (ja) | 2022-09-26 | 2025-10-15 | エッジワイズ セラピューティクス， インコーポレイテッド | １，４－ジヒドロキナゾリノン化合物およびその使用 |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| WO2024206347A1 (en) * | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Fused thiadiazine dioxide compounds and uses thereof |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242443B1 (en) * | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
| KR20000057444A (ko) * | 1996-12-09 | 2000-09-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 심기능부전 및 심실확장의 치료 및 예방 방법 |
| WO1998049146A2 (en) * | 1997-04-28 | 1998-11-05 | The United States Of America, Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health | Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer |
| JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用 |
| AU4932299A (en) | 1999-07-30 | 2001-02-19 | Yoshikane Ikitake | Reciprocating vane type rotary internal combustion engine |
| PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| IL154946A0 (en) | 2000-10-26 | 2003-10-31 | Pfizer Prod Inc | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| BR0114913A (pt) | 2000-10-26 | 2003-07-01 | Pfizer Prod Inc | Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona |
| PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
-
2002
- 2002-01-11 MX MXPA03005870A patent/MXPA03005870A/es unknown
- 2002-01-11 DE DE60201665T patent/DE60201665T2/de not_active Expired - Fee Related
- 2002-01-11 BR BR0207865-1A patent/BR0207865A/pt not_active IP Right Cessation
- 2002-01-11 EP EP02740094A patent/EP1368327B1/en not_active Expired - Lifetime
- 2002-01-11 ES ES02740094T patent/ES2231708T3/es not_active Expired - Lifetime
- 2002-01-11 WO PCT/IB2002/000083 patent/WO2002064578A1/en not_active Ceased
- 2002-01-11 JP JP2002564511A patent/JP2004518726A/ja not_active Abandoned
- 2002-01-11 AT AT02740094T patent/ATE280164T1/de not_active IP Right Cessation
- 2002-01-11 CA CA002433075A patent/CA2433075A1/en not_active Abandoned
- 2002-02-01 DO DO2002000336A patent/DOP2002000336A/es unknown
- 2002-02-05 PA PA20028538501A patent/PA8538501A1/es unknown
- 2002-02-07 GT GT200200016A patent/GT200200016A/es unknown
- 2002-02-08 UY UY27155A patent/UY27155A1/es not_active Application Discontinuation
- 2002-02-11 HN HN2002000227A patent/HN2002000227A/es unknown
- 2002-02-12 PE PE2002000109A patent/PE20020953A1/es not_active Application Discontinuation
- 2002-02-13 US US10/074,646 patent/US6656932B2/en not_active Expired - Fee Related
- 2002-02-13 TN TNTNSN02013A patent/TNSN02013A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1368327B1 (en) | 2004-10-20 |
| TNSN02013A1 (fr) | 2005-12-23 |
| DOP2002000336A (es) | 2003-01-31 |
| GT200200016A (es) | 2002-10-01 |
| UY27155A1 (es) | 2002-09-30 |
| JP2004518726A (ja) | 2004-06-24 |
| US6656932B2 (en) | 2003-12-02 |
| DE60201665T2 (de) | 2006-02-02 |
| DE60201665D1 (de) | 2004-11-25 |
| BR0207865A (pt) | 2004-03-23 |
| ES2231708T3 (es) | 2005-05-16 |
| CA2433075A1 (en) | 2002-08-22 |
| US20020156069A1 (en) | 2002-10-24 |
| ATE280164T1 (de) | 2004-11-15 |
| MXPA03005870A (es) | 2005-02-14 |
| PA8538501A1 (es) | 2002-09-17 |
| WO2002064578A1 (en) | 2002-08-22 |
| PE20020953A1 (es) | 2002-10-25 |
| EP1368327A1 (en) | 2003-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2002000227A (es) | Inhibidores de benzotiadiazina de metaloproteinasas de la matriz | |
| EA200200976A1 (ru) | Способ лечения или ингибирования полипов ободочной кишки | |
| EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
| NO953305D0 (no) | Antranilsyrederivat | |
| IS6309A (is) | Kínasólínafleiður | |
| EA200100411A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
| EA199800579A1 (ru) | Новые производные 5-амино-3-циано-4-этилсульфинил-1-фенилпиразола и их применение в качестве пестицидов | |
| IS6275A (is) | Heteróhringa efnasambönd og notkun þeirra sem mótlyf efnaskiptaglútamatviðtaka | |
| DE60317198D1 (de) | Proteinkinaseinhibitoren | |
| EA199800141A1 (ru) | Гетероциклические соединения | |
| ATE457025T1 (de) | Kinaseinhibitoren | |
| DK1485359T3 (da) | Natriumkanalblokkere | |
| ATE349435T1 (de) | Dpiv-inhibitoren auf glutaminbasis | |
| BR9609744A (pt) | Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2 | |
| DK1109817T3 (da) | Phosphohalogenhydriner, deres fremstilling og anvendelse | |
| ATE189227T1 (de) | Polyanionische benzyl-glykosiden als inhibitoren zur glatten-muskelzellen-proliferation | |
| EA200300982A1 (ru) | Гетероциклические производные для лечения рака и других пролиферативных заболеваний | |
| ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
| ES2193241T3 (es) | Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas. | |
| DK0828721T3 (da) | 2-Aminobenzoxazinoner til behandling af virale infektioner | |
| DK1532131T3 (da) | Motilid-forbindelser | |
| EA200100040A1 (ru) | Химический синтез морфолиновых производных | |
| BRPI0416678A (pt) | pirazolpirimidinas | |
| BR0200414A (pt) | Sulfonamidas como inibidores de metaloproteinase da matriz | |
| ATE243695T1 (de) | 5-bicycloindolverbindungen |